scispace - formally typeset
Search or ask a question
Institution

Eli Lilly and Company

CompanyIndianapolis, Indiana, United States
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Receptor, Placebo, Insulin, Agonist


Papers
More filters
Journal ArticleDOI
TL;DR: How TREM2 may control the microglia response to Aβ and its impact on microglial senescence is discussed, as well as the interaction of TREM 2 with other molecules that are encoded by gene variants associated with AD and the hypothetical consequences of the cleavage of T REM2 from the cell surface.
Abstract: Genome-wide association studies have identified rare variants of the gene that encodes triggering receptor expressed on myeloid cells 2 (TREM2) - an immune receptor that is found in brain microglia - as risk factors for non-familial Alzheimer disease (AD). Furthermore, animal studies have indicated that microglia have an important role in the brain response to amyloid-β (Aβ) plaques and that TREM2 variants may have an impact on such a function. We discuss how TREM2 may control the microglial response to Aβ and its impact on microglial senescence, as well as the interaction of TREM2 with other molecules that are encoded by gene variants associated with AD and the hypothetical consequences of the cleavage of TREM2 from the cell surface.

294 citations

Journal ArticleDOI
TL;DR: Intravenous sivelestat had no effect on 28-day all-cause mortality or ventilator-free days in a heterogeneous acute lung injury patient population managed with low tidal volume mechanical ventilation.
Abstract: Objective:Neutrophil elastase is believed to be an important mediator of acute lung injury. Sivelestat (ONO-5046, Elaspol) is a small molecular weight inhibitor of neutrophil elastase. The primary objectives of this study were to determine whether sivelestat would reduce 28-day all-cause mortality o

294 citations

Journal ArticleDOI
TL;DR: Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD.

294 citations

Journal ArticleDOI
Peter Nash1, Bruce Kirkham2, Masato Okada3, Proton Rahman4, B. Combe5, Gerd Burmester6, David H. Adams7, Lisa Kerr7, Chin Lee7, Catherine L Shuler7, Mark C. Genovese8, Khalid Ahmed, Jeffrey Alper, Nichol Barkham, Ralph E. Bennett, Francisco Javier Blanco Garcia, Ricardo Blanco Alonso, Howard B. Blumstein, Michael S. Brooks, Gerd R Burmester6, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der Yuan Chen, Melvin Churchill, Christine E Codding, Peter M.G. Deane, Jose Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilova, Rita M. Egan, Andrea Everding, Eva Galíndez, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert M. Griffin, Ramesh C. Gupta, Stephen B. Hall, Kalpita Hatti, Mary P. Howell, Yu-Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz P. Korkosz, Roshan Kotha, Joel M. Kremer, Cummins Lue, José Luis Marenco de la Fuente, Helena Marzo-Ortega, Jordi Gratacós Masmitjà, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama C. Nandagudi, Antonio Fernández-Nebro, Clark M. Neuwelt, Ana Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell-Bakalarska, David H. Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David H. Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen-Fang Tsai, Anthony M. Turkiewicz, Leonore Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielinska 
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.

294 citations

Journal ArticleDOI
TL;DR: Using polymerase chain reaction amplification of reverse‐transcribed RNA isolated from adult rat satellite cells, a temporal sequence of gene activation is demonstrated, distinct from that previously observed in embryonic somitic cells.
Abstract: The satellite cell is responsible for growth and repair of postnatal skeletal muscle. We investigated the expression of the myogenic regulatory gene (MRG) family in these cells in the stages from quiescence to fusion. Using polymerase chain reaction amplification of reverse-transcribed RNA (RT-PCR) isolated from adult rat satellite cells, we demonstrated a temporal sequence of gene activation, which is distinct from that previously observed in embryonic somitic cells. No MRG expression was detected in predominantly quiescent cells. MyoD is activated by 12 h in cell culture, prior to the first evidence of proliferation. MRF4 and myf-5 appear by 48 h and may be associated with the first division cycle. Myogenin is not detectable until 72 h after satellite cell recovery from the muscle fiber, coincidental with the first evidence of differentiation. © 1994 wiley-Liss, Inc.

293 citations


Authors

Showing all 17866 results

NameH-indexPapersCitations
Mark J. Daly204763304452
Irving L. Weissman2011141172504
Eric J. Topol1931373151025
Tony Hunter175593124726
Xiang Zhang1541733117576
Jerrold M. Olefsky14359577356
Stephen F. Badylak13353057083
George A. Bray131896100975
Lloyd Paul Aiello13150685550
Levi A. Garraway12936699989
Mark Sullivan12680263916
James A. Russell124102487929
Tony L. Yaksh12380660898
Elisabetta Dejana12243048254
Hagop S. Akiskal11856550869
Network Information
Related Institutions (5)
Pfizer
37.4K papers, 1.6M citations

98% related

Merck & Co.
48K papers, 1.9M citations

97% related

Novartis
50.5K papers, 1.9M citations

97% related

Hoffmann-La Roche
43K papers, 1.6M citations

93% related

National Institutes of Health
297.8K papers, 21.3M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20236
202287
2021815
2020868
2019732
2018742